Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 12
  1. Jun 01, 2026 · 14:50 · TTI · Routine −

    Thiogenesis Upsizes Cystinosis Cash Raise as Clinical Runway Extends, But Dilution Weighs on Near-Term Sentiment

    Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

    01
  2. Jun 01, 2026 · 09:00 · PCRX · Routine +

    PharmaCorp Rx Inc. Consolidates Eastern Canada Footprint as Q1 Revenue Surges 79%, Yet Margin Compression and Integration Pace Demand Caution

    PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results

    02
  3. Jun 01, 2026 · 08:02 · NRX · Neutral

    NurExone Advances Preclinical Milestones and Secures Minor Capital, But Cash Runway Narrows as Burn Rate Accelerates

    NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

    03
  4. Jun 01, 2026 · 07:30 · BCT · Routine +

    BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

    BriaCell Presents Positive Clinical Data at ASCO 2026

    04
  5. Jun 01, 2026 · 06:59 · BLCO · Routine +

    Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

    Bausch + Lomb Launches Blink(TM) Triple Care Preservative Free Lubricant Eye Drops in the United States

    05
  6. May 31, 2026 · 19:59 · BCT · Material −

    BriaCell Therapeutics Announces Pricing of Offering

    BriaCell Therapeutics Announces Pricing of Offering

    06
  7. May 31, 2026 · 03:20 · BCT

    Briacell prices shares of $4.7M offering at $3.25 each

    Briacell prices shares of $4.7M offering at $3.25 each

    07
  8. May 29, 2026 · 18:00 · KDA · Routine −

    KDA Group Settles Debt with Equity Amidst Share Price Collapse

    KDA GROUP COMPLETES DEBT SETTLEMENT

    08
  9. May 29, 2026 · 17:32 · VVTM · Routine −

    VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows

    VVT Med Provides Update on Management Cease Trade Order

    09
  10. May 29, 2026 · 17:05 · TLT · Routine +

    Theralase Confirms Bladder Cancer Efficacy Ahead of FDA Filing; Dilution Concerns Weigh on Shares

    Theralase(R) Releases Q1 2026 Financial Statements

    10
  11. May 29, 2026 · 17:00 · QPT · Routine +

    Quest PharmaTech Posts Profit But Relies Heavily on Private Equity Valuation Amid Reporting Shift

    Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis

    11
  12. May 29, 2026 · 08:30 · MVMD · Routine +

    MVMD Advances Peptide Platform Ahead of July FDA Catalyst, Balance Sheet Fortified by Recent Financing

    Mountain Valley MD Advances Quicksome(TM) Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157

    12
  13. May 29, 2026 · 07:30 · APS · Neutral

    Aptose Deal Closing Delayed to June; Hanmi Funding Secures Runway Amidst Regulatory Hurdles

    Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

    13
  14. May 29, 2026 · 07:00 · EDT · Routine +

    Spectral Medical Files FDA PMA for PMX Amidst Tight Cash Runway

    Spectral Medical Announces PMA Submission to U.S. FDA for PMX

    14
← Newer Older →